Wanbangde Pharmaceutical Holding Group Co., Ltd. (SHE:002082)
China · Delayed Price · Currency is CNY 12.97
+0.16 (1.25%)
Sep 30, 2026, 3:04 PM CST
SHE:002082 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 7,934 | 8,521 | 3,933 | 3,915 | 5,409 | 9,082 | |
Market Cap Growth | 18.99% | 116.64% | 0.47% | -27.62% | -40.45% | 7.23% |
Enterprise Value | 8,467 | 9,445 | 4,899 | 4,825 | 5,870 | 9,910 |
Last Close Price | 12.97 | 13.93 | 6.43 | 6.28 | 8.51 | 14.27 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | 70.94 | 79.56 | 58.00 | 54.55 |
Forward PE | - | 6.44 | 6.44 | 6.44 | 6.44 | 6.44 |
PS Ratio | 7.04 | 7.63 | 2.73 | 2.54 | 3.03 | 4.70 |
PB Ratio | 2.98 | 3.27 | 1.43 | 1.42 | 1.92 | 3.31 |
P/TBV Ratio | 4.22 | 4.72 | 1.89 | 1.85 | 2.54 | 4.53 |
P/FCF Ratio | 16.44 | 28.18 | 170.18 | - | - | - |
P/OCF Ratio | 12.77 | 14.11 | 32.72 | - | - | 411.24 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 7.51 | 8.45 | 3.39 | 3.13 | 3.29 | 5.13 |
EV/EBITDA Ratio | 220.13 | - | 27.56 | 29.42 | 17.40 | 32.48 |
EV/EBIT Ratio | - | - | 63.91 | 68.74 | 25.24 | 47.04 |
EV/FCF Ratio | 17.55 | 31.24 | 211.95 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.38 | 0.43 | 0.37 | 0.35 | 0.31 | 0.31 |
Debt / EBITDA Ratio | 26.48 | - | 5.69 | 5.84 | 2.55 | 2.76 |
Debt / FCF Ratio | 2.11 | 3.69 | 44.49 | - | - | - |
Net Debt / Equity Ratio | 0.17 | 0.22 | 0.31 | 0.27 | 0.14 | -0.02 |
Net Debt / EBITDA Ratio | 12.52 | -14.85 | 4.83 | 4.57 | 1.18 | -0.23 |
Net Debt / FCF Ratio | 0.93 | 1.88 | 37.14 | -3.72 | -0.97 | 0.26 |
Asset Turnover | 0.26 | 0.26 | 0.34 | 0.36 | 0.42 | 0.39 |
Inventory Turnover | 2.89 | 3.30 | 3.61 | 3.41 | 3.13 | 1.80 |
Quick Ratio | 0.96 | 0.92 | 0.93 | 1.09 | 1.57 | 1.63 |
Current Ratio | 1.28 | 1.23 | 1.37 | 1.45 | 1.94 | 1.92 |
Return on Equity (ROE) | -4.55% | -6.41% | 1.64% | 0.94% | 2.65% | 5.75% |
Return on Assets (ROA) | -1.05% | -2.00% | 1.11% | 1.03% | 3.38% | 2.63% |
Return on Invested Capital (ROIC) | -2.37% | -4.11% | 1.65% | 1.84% | 5.81% | 2.75% |
Return on Capital Employed (ROCE) | -2.50% | -4.60% | 2.50% | 2.40% | 7.50% | 6.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -1.48% | -1.96% | 1.41% | 1.26% | 1.72% | 1.83% |
FCF Yield | 6.08% | 3.55% | 0.59% | -5.15% | -7.52% | -2.90% |
Dividend Yield | - | - | - | 1.27% | 1.41% | - |
Payout Ratio | - | - | 163.85% | 247.98% | 47.08% | 115.10% |
Buyback Yield / Dilution | 8.63% | -0.55% | -0.15% | 1.06% | -0.82% | -1.73% |
Total Shareholder Return | 8.63% | -0.55% | -0.15% | 2.34% | 0.59% | -1.73% |